WESPAC Advisors SoCal’s Neurocrine Biosciences NBIX Stock Holding History

WESPAC Advisors SoCal’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,465	Closed	-$236K	–	80
2020 Q4	$236K	Hold	2,465	–	–	0.09%	70
2020 Q3	$257K	Hold	2,465	–	–	0.12%	64
2020 Q2	$320K	Hold	2,465	–	–	0.15%	61
2020 Q1	$244K	Hold	2,465	–	–	0.14%	64
2019 Q4	$265K	Hold	2,465	–	–	0.13%	72
2019 Q3	$222K	Hold	2,465	–	–	0.11%	78
2019 Q2	$208K	Hold	2,465	–	–	0.11%	83
2019 Q1	$217K	Hold	2,465	–	–	0.12%	85
2018 Q4	$176K	Hold	2,465	–	–	0.11%	84
2018 Q3	$303K	Hold	2,465	–	–	0.15%	72
2018 Q2	$242K	Buy	2,465 +1,800	+271%	+$161K	0.14%	76
2018 Q1	$55K	Hold	665	–	–	0.03%	110
2017 Q4	$51K	Buy	+665	New	+$45.4K	0.03%	117

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

WESPAC Advisors SoCal's NBIX Position: Q1 2021 in Review

WESPAC Advisors SoCal sold out of Neurocrine Biosciences (NBIX) in Q1 2021, closing a stake of 2,465 shares — an estimated $236K sold.

WESPAC Advisors SoCal first reported a position in NBIX in Q4 2017 and held it in 13 quarters. The position peaked at $320K in Q2 2020. 419 funds tracked by Wall St. Rank hold NBIX as of Q1 2021.

WESPAC Advisors SoCal reported no remaining Neurocrine Biosciences position as of Q1 2021 after selling out during the quarter.
WESPAC Advisors SoCal sold 2,465 Neurocrine Biosciences shares in Q1 2021, an estimated $236K.
WESPAC Advisors SoCal first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 13 quarters.
WESPAC Advisors SoCal's Neurocrine Biosciences position peaked at $320K in Q2 2020.
419 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2021.

Based on WESPAC Advisors SoCal's 13F filing for Q1 2021, filed 30 Apr 2021.